# OMEGA, Local Ablative Therapy in Oligometastatic NSCLC

> **NCT03827577** · PHASE3 · UNKNOWN · sponsor: **Azienda Ospedaliera Universitaria Integrata Verona** · enrollment: 195 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **PROCEDURE:** Surgical removal of primary and/or of all oligometastases
- **RADIATION:** Non-surgical LAT
- **DRUG:** Standard medical therapy

## Key facts

- **NCT ID:** NCT03827577
- **Lead sponsor:** Azienda Ospedaliera Universitaria Integrata Verona
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2022-03
- **Final completion:** 2022-09
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03827577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03827577, "OMEGA, Local Ablative Therapy in Oligometastatic NSCLC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03827577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*